<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02293759</url>
  </required_header>
  <id_info>
    <org_study_id>Mans-2014-04</org_study_id>
    <nct_id>NCT02293759</nct_id>
  </id_info>
  <brief_title>Trial of HoLEP vs. PVP in Treating BPH in Patients With Bleeding Tendency</brief_title>
  <official_title>Prospective Non-randomized Trial Comparing Holmium Laser Enucleation of the Prostate Versus Greenlight Laser Photoselective Vaporization of the Prostate in Treating Benign Prostate Hyperplasia in Patients With Bleeding Tendency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mansoura University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mansoura University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients presented for BPH surgery at our out patient clinic will be assessed for abnormal
      bleeding profile.

      Patients with bleeding tendency will be offered either HoLEP or Greenlight laser PVP based on
      prostate size cut off point of 80ml Larger prostates will be treated with HoLEP Smaller
      prostates will be treated with greenlight PVP
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Elderly patients with bleeding tendency either secondary;

        1. Strict antiplatelet intake

        2. Strict anticoagulant intake

        3. uncorrected natural bleeding tendency e.g; patients with liver cell failure are at
           higher risk of perioperative bleeding when subjected to prostate surgery.

      Laser prostate surery was introduced to overcome this difficulty. However, till now there is
      no head to head comparision of different types of laser procedures in treating this subset of
      patients In the current study patients presented for BPH surgery in a tertiarry referral
      prostate unit will be assessed for bleeding tendency and will be treated either by Holmium
      laser enucleatiuon of the prostate or Greenlight laser vaporization of the prostate Single
      surgeon will perform all cases
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Anticipated">August 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>perioperative blood loss</measure>
    <time_frame>48 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>readmission</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood transfusion</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>flow rate</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Benign Prostatic Hyperplasia</condition>
  <arm_group>
    <arm_group_label>HoLEP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Holmium laser enucleation of the prostate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Greenlight laser PVP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Phtoselective vaporization of the prostate</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>HoLEP</intervention_name>
    <description>Holmium laser enucleation of the prsotate</description>
    <arm_group_label>HoLEP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Greenlight laser PVP</intervention_name>
    <description>Greenlight laser (532nm) Photoslective vaporization of the prostate</description>
    <arm_group_label>Greenlight laser PVP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BPH patients candidate for transurethral prostate surgery after failure of medical
             treatment

          -  Perioperative uncorrected Blleding tendency

               1. patients with naturally induced uncorrectable bleeding tendency;

                    1. platelet count less than 100000/mm3

                    2. INR more than 1.5

               2. Patients on oral antiplatlet that deemed unsafe to stop prior to surgery as per
                  intenist

               3. Patients on oral anticoagulant that deemed unsafe to stop prior to surgery as per
                  intenist

        Exclusion Criteria:

          -  Correctable bleeding tendency
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmed m Elshal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mansoura Urology and Nephrology Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ahmed m Elshal, MD</last_name>
    <phone>+20502262222</phone>
    <phone_ext>1428</phone_ext>
    <email>ELSHALAM@GMAIL.COM</email>
  </overall_contact>
  <location>
    <facility>
      <name>Urology and Nephrology Center</name>
      <address>
        <city>Mansoura</city>
        <state>Aldakahlia</state>
        <zip>35516</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmed M Elshal, MD</last_name>
      <phone>00201001855490</phone>
      <email>elshalam@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Ahmed M Elshal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ahmed M Elasmy, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ahmed R El-Nahas, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 13, 2014</study_first_submitted>
  <study_first_submitted_qc>November 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2014</study_first_posted>
  <last_update_submitted>March 27, 2016</last_update_submitted>
  <last_update_submitted_qc>March 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mansoura University</investigator_affiliation>
    <investigator_full_name>Ahmed Elshal</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <keyword>BPH- LASER- PROSTATE- BLEEDING TENDENCY</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Blood Coagulation Disorders</mesh_term>
    <mesh_term>Hemostatic Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

